ACAD vs INDV
ACADIA Pharmaceuticals Inc. vs Indivior Pharmaceuticals Inc — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
69
Buy
VS
INDV
Indivior Pharmaceuticals Inc
58
Watch
| Metric | ACAD | INDV |
|---|
| AI Score |
69
|
58
|
| Price |
$29.41
|
$38.42
|
| P/E Ratio |
13.07×
|
13.53×
|
| ROE |
31.9%
|
-214.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
83.9%
|
| Debt / Equity |
0.06×
|
-2.45×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
78.4
|
42.6
|
| Beta |
0.845
|
1.0251
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ACAD versus INDV.
ACAD leads by 11 points.
ACAD scores 69/100 (Buy) versus INDV at 58/100 (Watch).
ACAD Committee View
83% agreement
6 analysts
The primary driver is revenue growing 47.0% yoy -- genuine top-line momentum. The main limiting factor is bollinger bandwidth of 24.3% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- P/E of 13.2 is inexpensive for the broad market — Value
- ROE of 32.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
Bear Case
- RSI at 78 is in overbought territory — Technical
- Weekly RSI at 80 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 24.3% signals elevated volatility — Risk
INDV Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — high leverage (debt-to-equity 5.43) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- P/E of 12.8 is inexpensive for the broad market — Value
- ROE of 159.1% shows genuine earnings power backing the valuation — Value
- EPS growing 237.5% YoY — Growth
Bear Case
- Price-to-book of 49.6x prices in significant intangible value — Value
- Debt-to-equity of 5.43 adds balance-sheet risk to the value case — Value
- MACD histogram negative -- bearish momentum — Technical